局部晚期鼻咽癌免疫治疗的研究现状及展望  

Current status and prospects of immunotherapy for locally advanced nasopharyngeal carcinoma

作　　者：刘溪溪 孙亚洁 杨坤禹 LIU Xixi;SUN Yajie;YANG Kunyu(Cancer Center,Union Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430022,China;Institute of Radiation Oncology,Union Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430022,China;Hubei Key Laboratory of Precision Radiation Oncology,Wuhan 430022,China)

机构地区：[1]华中科技大学同济医学院附属协和医院肿瘤中心,武汉430022 [2]华中科技大学同济医学院附属协和医院肿瘤放射治疗研究所,武汉430022 [3]肿瘤精准放射治疗湖北省重点实验室,武汉430022

出　　处：《广西医科大学学报》2024年第9期1296-1303,共8页Journal of Guangxi Medical University

基　　金：国家自然科学基金资助项目(No.82073354);肿瘤精准放射治疗湖北省重点实验室开放课题基金(No.jzfs006)。

摘　　要：鼻咽癌(NPC)是一种起源于鼻咽上皮黏膜的鳞状细胞癌,与EB病毒感染密切相关,以中国南方最为常见。免疫治疗,尤其是免疫检查点抑制剂在多种实体肿瘤中显示出较好的疗效和可靠的安全性,包含复发转移性NPC。另外,免疫治疗在局晚期NPC的治疗领域中也取得了新突破,许多临床研究正在进行中。本文将立足于已经报道的研究结果,通过介绍NPC免疫治疗的基本原理、免疫治疗的研究现状,全面概述NPC免疫治疗领域的进展和挑战,期望为今后NPC的临床实践和研究提供参考。Nasopharyngeal carcinoma(NPC)is a squamous cell carcinoma arising from the nasopharyngeal epithelium,which is associated with Epstein-Barr virus(EBV)infection and is most common in southern China.Immunotherapy,particularly immune checkpoint inhibitors(ICIs),provides favorable efficacy with a good safety profile in a variety of solid tumors,including recurrent or metastatic NPC(R/M-NPC).In addition,immunotherapy has made new breakthroughs in the treatment of locally advanced NPC,and many clinical studies are underway.Based on previously reported results,this study presents a comprehensive overview of the advances and challenges by introducing the basic principles and the current status of immunotherapy in NPC,with the expectation that it will serve as a reference for clinical practice in the future.

关 键 词：程序性细胞死亡受体-1 免疫治疗 临床研究 鼻咽癌 

分 类 号：R739.63[医药卫生—肿瘤]